Navigation Links
Published Study Shows VNUS ClosureFAST™ System Significantly Superior to Laser for Varicose Vein Treatment

Journal of Vascular & Interventional Radiology Cites Improved Recovery and Quality-of-Life with VNUS Technology

San Jose, CA (PRWEB) June 10, 2009 -- VNUS® Medical Technologies, Inc. (NASDAQ: VNUS), a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, announced today that the Journal of Vascular & Interventional Radiology, the prestigious monthly publication of the Society of Interventional Radiology, has published a study showing the VNUS ClosureFAST™ system for radiofrequency (RF) thermal ablation to be "significantly superior" to endovenous laser (EVL) for treating venous reflux, the underlying cause of symptomatic varicose veins.

The VNUS ClosureFAST catheter is a minimally invasive device generally used in the physician's office with a local anesthetic to heat and seal the great saphenous vein, the most common site of venous reflux in the leg. The RECOVERY trial was a multicenter, randomized, single-blinded study of 87 vein ablation procedures in 69 patients, comparing the ClosureFAST radiofrequency catheter to the 980 nm endovenous laser system. The study found that for all primary endpoints in the trial, the ClosureFAST radiofrequency catheter was statistically superior to laser treatment in providing a fast and comfortable recovery for the patient after treatment. Specifically, radiofrequency vein ablation using the ClosureFAST catheter was shown to result in less postoperative pain, less bruising, less tenderness, and better reduction of symptoms than laser as soon as two days after treatment, and remaining considerably better for at least two weeks or longer. In addition, all statistical differences in post procedural and quality-of-life parameters were superior in the ClosureFAST group, and minor complications were five times less prevalent.

"The study found RF thermal ablation, as performed with the ClosureFAST catheter, superior to EVL as measured by a comprehensive array of postprocedural recovery and QOL comparisons between these two minimally invasive techniques for closure of the greater saphenous vein," said Jose I. Almeida, M.D., lead author of the study and Medical Director of Miami Vein Center.

"The study confirms what many of us who have used both laser and radiofrequency devices have felt subjectively - that there is significantly enhanced patient comfort with the radiofrequency technology," said Raymond G. Makhoul, M.D., of Richmond, Virginia, a researcher for the study. "The ClosureFAST device clearly provided a superior patient experience."

"This study emphatically supports the experience of our customers who frequently describe the ease of use of our ClosureFAST radiofrequency catheter and the rapid and mild recovery of patients treated with the catheter," said Brian E. Farley, President and CEO of VNUS. "The trial data also explains the enthusiastic adoption of our technology by the physician community. The publication of the RECOVERY Trial results complements other medical journal publications showing over 97% efficacy from the ClosureFAST catheter. Together with the positive endorsement from European national health authorities, we believe this therapy can be regarded as the premier technology for the treatment of venous reflux disease, a medical condition afflicting millions of people worldwide."

Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (NASDAQ: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that is the underlying cause of varicose veins. VNUS sells the Closure system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to treat diseased veins through the application of temperature-controlled RF energy. For more information, please visit


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Two studies published in the Lancet
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. New report on mobile phone research published
5. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
6. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
7. Clinical Study Published Showing Benefits of Glue Used in Facelift Surgery
8. New tool to assess excessive daytime sleepiness in adolescents published in JCSM
9. Published Results Using AtriCure Minimally Invasive Products
10. Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue
11. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
Post Your Comments:
Related Image:
Published Study Shows VNUS ClosureFAST™ System Significantly Superior to Laser for Varicose Vein Treatment
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: